Article
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
Cancer - 15 Dec 2010
da Cunha Santos Gilda, Dhani Neesha, Tu Dongsheng, Chin Kayu, Ludkovski Olga, Kamel-Reid Suzanne, Squire Jeremy, Parulekar Wendy, Moore Malcolm J, Tsao Ming Sound
Abstract excerpt
BACKGROUND: National Cancer Institute of Canada Clinical Trials Group PA.3 (NCIC CTG PA.3) was a phase 3 study (n = 569) that demonstrated benefits for overall survival and progression-free survival with the addition of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib to gemcitabine in patients with advanced pancreatic carcinoma (APC). Mutation status of the v-Ki-ras2 Kirsten...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.